Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer

被引：9

作者：

Aurilio, Gaetano ^{[1
]}

Sandri, Maria Teresa ^{[2
]}

Pruneri, Giancarlo ^{[3
,4
]}

Zorzino, Laura ^{[2
]}

Botteri, Edoardo ^{[5
]}

Munzone, Elisabetta ^{[1
]}

Adamoli, Laura ^{[1
]}

Facchi, Giuseppina ^{[2
]}

Cullura, Daniela ^{[1
]}

Verri, Elena ^{[1
]}

Rocca, Maria Cossu ^{[1
]}

Zurrida, Stefano ^{[6
]}

Iacovelli, Roberto ^{[1
]}

Nole, Franco ^{[1
]}

机构：

[1] European Inst Oncol, Med Oncol, Via Ripamonti 435, Milan, Italy

[2] European Inst Oncol, Lab Med, Via Ripamonti 435, Milan, Italy

[3] European Inst Oncol, Div Pathol & Lab Med, Via Ripamonti 435, I-20122 Milan, Italy

[4] Univ Milan, Sch Med, I-20122 Milan, Italy

[5] European Inst Oncol, Div Epidemiol Biostat, Via Ripamonti 435, Milan, Italy

[6] European Inst Oncol, Div Senol, Via Ripamonti 435, Milan, Italy

来源：

FUTURE ONCOLOGY | 2016年 / 12卷 / 17期

关键词：

HER2 CTC status; metastatic breast cancer; serum HER2 ECD levels; survival; HER-2/NEU; TRASTUZUMAB; SURVIVAL; RECEPTOR; THERAPY; UTILITY; TRIAL; TIME;

D O I：

10.2217/fon-2016-0081

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: To shed light on the clinical role of HER2 status in serum as extracellular domain (ECD) and corresponding circulating tumor cells (CTCs) in metastatic breast cancer patients. Methods: 68 patients were analyzed. Serum HER2 was determined by ADVIA Centaur (R) Serum HER2 test. CellSearch System was performed for CTC quantification. Results: HER2 was overexpressed in 21 primary tumors. In total, 19 patients had ECD > 15 ng/ml (the cutoff used), 48 patients had at least one CTC. ECD positivity was associated with CTC number (p = 0.01), HER2-positive CTC (p = 0.01) and the ratio HER2-positive CTC/total CTC (p = 0.02). ECD was not associated with survival. Conclusion: ECD in combination with HER2 CTC status would deserve further investigation in larger series for addressing its putative prognostic relevance.

引用

页码：2001 / 2008

页数：8

共 50 条

[1] Reassessment of HER2 status in breast cancer patients at the time of metastatic disease by serum HER2 and HER2 status of circulating tumor cells
Fehm, Tania
TUMOR BIOLOGY, 2007, 28 : 22 - 22
[2] Reassessment of HER2 status in HER2 negative or HER2 unknown breast cancer patients with recurrent metastatic disease by analyzing serum HER2 and HER2 status of circulating tumor cells.
Fehm, T.
Lane, N.
Solomayer, E.
Wallwiener, D.
Uhr, J.
BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S40 - S40
[3] Successful targeting HER2 in heavily pretreated HER2-negative metastatic breast cancer patients presenting with elevated serum levels of the HER2 extracellular domain and/or HER2 overexpressing circulating tumor cells
Kurbacher, C. M.
Quade, A.
Eichler, C.
Kunstmann, G.
Herz, S.
Kurbacher, J. A.
Warm, M. R.
CANCER RESEARCH, 2016, 76
[4] Reassessment of HER2 status in breast cancer patients with initially HER2 negative or HER2 unknown primary tumors at the time of metastatic disease by serum HER2 and HER2 status of circulating tumor cells
Fehm, T.
Solomayer, E.
Uhr, J.
Wallwiener, D.
ONKOLOGIE, 2008, 31 : 51 - 51
[5] Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer
Kong, Sun-Young
Nam, Byung-Ho
Lee, Keun Seok
Kwon, Youngmee
Lee, Eun Sook
Seong, Moon-Woo
Lee, Do Hoon
Ro, Jungsil
CLINICAL CHEMISTRY, 2006, 52 (08) : 1510 - 1515
[6] Targeting HER2 in patients with HER2-negative metastatic breast cancer with elevated serum levels of the HER2 extracellular domain and/or HER2-positive circulating tumor cells in the clinical routine
Kurbacher, C. M.
Quade, A.
Kunstmann, G.
Herz, S.
Kurbacher, J. A.
Warm, M. A.
ANNALS OF ONCOLOGY, 2015, 26
[7] Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
Tanja Fehm
Sven Becker
Silke Duerr-Stoerzer
Karl Sotlar
Volkmar Mueller
Diethelm Wallwiener
Nancy Lane
Erich Solomayer
Jonathan Uhr
Breast Cancer Research, 9
[8] Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
Fehm, Tanja
Becker, Sven
Duerr-Stoerzer, Silke
Sotlar, Karl
Mueller, Volkmar
Wallwiener, Diethelm
Lane, Nancy
Solomayer, Erich
Uhr, Jonathan
BREAST CANCER RESEARCH, 2007, 9 (05) : R74
[9] Serum HER2 extracellular domain as a potential alternative for tissue HER2 status in metastatic gastric cancer patients
Peng, Zhi
Liu, Yi
Li, Yanyan
Zhang, Xiaotian
Zhou, Jun
Lu, Ming
Li, Qingqing
Shen, Lin
BIOMARKERS IN MEDICINE, 2014, 8 (05) : 663 - 670
[10] SUCCESSFUL USE OF HER2 TARGETED AGENTS IN PATIENTS WITH HEAVILY PRETREATED HER2-NEGATIVE METASTATIC BREAST CANCER PRESENTING WITH ELEVATED SERUM LEVELS OF THE HER2 EXTRACELLULAR DOMAIN AND/OR HER2 OVEREXPRESSING CIRCULATING TUMOR CELLS
Kurbacher, Christian Martin
Quade, Annegret
Kunstmann, Gerhard
Herz, Susanne
Kurbacher, Jutta Anna
Warm, Matthias R.
BREAST, 2015, 24 : S70 - S70

← 1 2 3 4 5 →